Dashboard
Manage Tickers

LFCR LIFECORE BIOMEDICAL, INC. \DE\

Nasdaq www.landec.com


$ 7.89 $ -0.33 (-4.01 %)    

Thursday, 13-Nov-2025 15:59:58 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 606.68 $ 0.00 (0 %)
DIA $ 474.53 $ 0.00 (0 %)
SPY $ 671.33 $ 0.00 (0 %)
TLT $ 89.22 $ 0.00 (0 %)
GLD $ 383.81 $ 0.00 (0 %)
$ 7.89
$ 8.22
$ 6.68 x 100
$ 11.00 x 20
-- - --
$ 4.76 - $ 8.85
212,639
na
295.61M
$ 0.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 05-25-2025 10-K
3 04-03-2025 02-23-2025 10-Q
4 01-02-2025 11-24-2024 10-Q
5 10-04-2024 08-25-2024 10-Q
6 08-26-2024 05-26-2024 10-K
7 08-09-2024 08-27-2023 10-Q
8 08-09-2024 11-26-2023 10-Q
9 08-09-2024 02-25-2024 10-Q
10 03-20-2024 05-28-2023 10-K
11 06-02-2023 02-26-2023 10-Q
12 03-16-2023 11-27-2022 10-Q
13 10-07-2022 08-28-2022 10-Q
14 09-14-2022 05-29-2022 10-K
15 04-07-2022 02-27-2022 10-Q
16 01-07-2022 11-28-2021 10-Q
17 10-05-2021 08-29-2021 10-Q
18 07-29-2021 05-30-2021 10-K
19 04-08-2021 02-28-2021 10-Q
20 01-07-2021 11-29-2020 10-Q
21 10-07-2020 08-30-2020 10-Q
22 08-14-2020 05-31-2020 10-K
23 04-03-2020 02-23-2020 10-Q
24 01-02-2020 11-24-2019 10-Q
25 10-03-2019 08-25-2019 10-Q
26 08-01-2019 05-26-2019 10-K
27 04-04-2019 02-24-2019 10-Q
28 01-07-2019 11-25-2018 10-Q
29 10-05-2018 08-26-2018 10-Q
30 08-09-2018 05-27-2018 10-K
31 04-05-2018 02-25-2018 10-Q
32 01-05-2018 11-26-2017 10-Q
33 09-28-2017 08-27-2017 10-Q
34 08-11-2017 05-28-2017 10-K
35 04-07-2017 02-26-2017 10-Q
36 01-05-2017 11-27-2016 10-Q
37 09-29-2016 08-28-2016 10-Q
38 08-01-2016 05-29-2016 10-K
39 03-30-2016 02-28-2016 10-Q
40 01-07-2016 11-29-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

lifecore-biomedical-affirms-fy2026-sales-guidance-of-74000m-76000m-vs-131882m-est
Lifecore Biomedical Affirms FY2026 Sales G...
11/06/2025 21:26:37

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $74.000 million-$76.000 million to $74.000 million-$76.000 ...

lifecore-biomedical-q1-eps-029-beats-030-estimate-sales-31109m-beat-26471m-estimate
Lifecore Biomedical Q1 EPS $(0.29) Beats $...
11/06/2025 21:25:55

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $...

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

lifecore-expands-cdmo-business-becomes-supplier-of-choice-for-leading-injectable-drug
Lifecore Expands CDMO Business, Becomes Su...
10/29/2025 11:23:06

Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organiz...

lifecore-biomedical-and-polypeptide-form-strategic-collaboration-to-provide-fully-integrated-peptide-manufacturing-and-development-capabilities-for-us-customers
Lifecore Biomedical And PolyPeptide Form S...
10/28/2025 11:13:42

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/24/2025 17:06:12

lifecore-files-preliminary-prospectus-to-offer-up-to-150m-in-common-stock-and-warrants
Lifecore Files Preliminary Prospectus To O...
09/23/2025 10:11:36

keybanc-initiates-coverage-on-lifecore-biomedical-with-sector-weight-rating
Keybanc Initiates Coverage On Lifecore Bio...
09/04/2025 09:44:21

Keybanc analyst Paul Knight initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Sector Weight rating.

lifecore-biomedical-sees-fy2026-sales-74000m-76000m-vs-127802m-est
Lifecore Biomedical Sees FY2026 Sales $74....
08/07/2025 20:39:05

Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $74.000 million-$76.000 million vs $127.802 million analyst estimate.

lifecore-biomedical-q4-eps-006-beats-010-estimate-sales-36444m-beat-35363m-estimate
Lifecore Biomedical Q4 EPS $(0.06) Beats $...
08/07/2025 20:14:42

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

lifecore-signs-10-year-deal-to-make-eye-drug-boosting-long-term-revenue-growth-prospects
Lifecore Signs 10-Year Deal to Make Eye Dr...
06/17/2025 11:01:41

Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organiz...

lifecore-biomedical-receives-early-10m-payout-from-filler-sale-boosting-balance-sheet-and-supporting-300m-revenue-capacity-strategy
Lifecore Biomedical Receives Early $10M Pa...
06/12/2025 11:14:10

william-blair-initiates-coverage-on-lifecore-biomedical-with-outperform-rating
William Blair Initiates Coverage On Lifeco...
05/21/2025 18:04:11

William Blair analyst Max Smock initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Outperform rating.

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
04/04/2025 17:06:22

lifecore-biomedical-reiterates-fy25-revenue-1265m-130m-vs-128439m-est
Lifecore Biomedical Reiterates FY25 Revenu...
04/03/2025 20:09:04

lifecore-biomedical-q3-2025-gaap-eps-047-misses-015-estimate-sales-35154m-beat-33229m-estimate
Lifecore Biomedical Q3 2025 GAAP EPS $(0.4...
04/03/2025 20:08:06

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of...

earnings-scheduled-for-april-3-2025
Earnings Scheduled For April 3, 2025
04/03/2025 08:32:08

lifecore-biomedical-says-humanetics-selected-company-to-provide-range-of-cdmo-services-to-support-continued-development-of-bio-300-for-prevention-of-acute-radiation-syndrome
Lifecore Biomedical Says Humanetics Select...
03/17/2025 11:03:12

lifecore-biomedical-announces-17m-sales-agreement-for-10-head-isolator-filler-receives-7m-at-closing-expects-remaining-payments-in-3-tranches-over-18-months
Lifecore Biomedical Announces $17M Sales A...
01/07/2025 14:08:23

Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Mil...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION